2018 Payment Schedule Test Updates

The table below reflects Records of Decision associated with laboratory tests under the Laboratory Services Act in BC.

LSA ROD #

Approvals Granted

LSA2017-003

Fee revision and removal of provisional status of Anti-tissue transglutaminase antibodies (anti-TTG), IgA testing in the Laboratory Services Outpatient Payment Schedule. 

Effective June 1, 2018, the Ministry of Health has amended the fee amount for 91162, Anti-tissue transglutaminase antibodies (anti-TTG), IgA, from $24.18 to $13.92, and removed the provisional status in the Laboratory Services Outpatient Payment Schedule.

LSA2018-003

Introduction of two new fee items for MALDI-TOF testing in the Laboratory Services Outpatient Payment Schedule. 

Effective June 1, 2018, the Ministry of Health has approved the introduction of two new fee items, P90752 and P90753 for MALDI-TOF testing for stool and non-stool specimens, at the fee of $6.84, in the Laboratory Services Outpatient Payment Schedule. This Record of Decision (ROD) rescinds the October 25, 2017 ROD LSA2017-024.

LSA2018-005

Effective June 1, 2018, the Ministry of Health has amended the fee amount for five antinuclear antibody testing fee items in the Laboratory Services Outpatient Payment Schedule, as follows:

  1.  Fee item 90280 – Antinuclear antibodies – immunofluorescence screen from $23.82 to $20.44.
  2.  Fee item 90281 – Antinuclear antibodies by sensitive EIA from $17.76 to $16.24.
  3.  Fee item 90120 –Extractable Nuclear Antigens from $30.60 to $24.99.
  4.  Fee item 90121 – Antinuclear antibodies – specific detection by multiplex immunoassay from $27.65 to $38.64.
  5. Fee item 90035 – Anti DNA from $20.22 to $28.41.
LSA2018-002

Repatriation of Thiopurine Metabolites (TM) testing to British Columbia from out-of-province/out-of-country, and addition of a new Provisional (P) fee item P92277 – Thiopurine Metabolites, to the Laboratory Services Outpatient Payment Schedule.

Effective May 1, 2018, the Ministry of Health (MOH) has approved the addition of Thiopurine Metabolites (TM) testing on a provisional (P) basis for a one year period. Testing will be restricted to Victoria General Hospital and is restricted to referrals from specialists prescribing thiopurine medications, and to patients with active inflammatory bowel disease and/or adverse effects thought to be due to thiopurine toxicity.

LSA2017-023

Repatriation of infliximab and anti-infliximab antibody testing from Alberta to British Columbia.

Effective May 1, 2018, the Ministry of Health (MOH) has approved the repatriation and funding of Infliximab (IFX) and anti-infliximab antibody (IFXA) testing on a provisional basis (P) for a one year period. IFX and IFXA testing will be restricted to St. Paul’s Hospital (SPH).